Patrizio Vitulo appointed member of National Ethics Committee for Clinical Trials on Advanced Therapies.

Dr. Patrizio Vitulo, Head of the Pulmonology Unit and Director of the Phase I Clinical Trials Unit at IRCCS ISMETT, was appointed as member of the National Ethics Committee (CEN) for Clinical Trials on Advanced Therapy Medicinal Products (ATMPs).

Established by the Italian Ministry of Health, CEN ATMP is an independent body responsible for evaluating and authorizing clinical trials involving innovative biotechnological therapies — including gene therapies, cell therapies, and tissue therapies — ensuring the protection of participants’ rights, safety, and well-being, as well as adherence to the highest scientific and ethical standards.

Dr. Vitulo’s appointment is an important recognition of his clinical and scientific expertise in the field of translational medicine and clinical trials, developed at IRCCS ISMETT. His appointment also highlights IRCCS ISMETT’s ongoing commitment to advancing increasingly personalized and innovative treatments.

“It is an honor for me to join a strategic body for the advancement of clinical research in our country,” said Patrizio Vitulo. “Advanced therapies represent the cutting edge of innovation in treating many severe diseases or conditions lacking effective therapies. It is therefore essential to ensure that their clinical development fully adheres to ethical research principles while maintaining the centrality of the patient.”